Welcome to our dedicated page for Forian news (Ticker: FORA), a resource for investors and traders seeking the latest updates and insights on Forian stock.
Forian Inc. (Nasdaq: FORA) stands at the forefront of delivering advanced data science-driven solutions and analytics to the healthcare and life sciences sectors. With a comprehensive suite of Software as a Service (SaaS) tools, data management capabilities, and proprietary analytics, Forian is dedicated to optimizing and measuring operational, clinical, and financial performance. Their offerings cater to a wide range of clients including traditional and emerging life sciences companies, healthcare payers and providers, as well as cannabis dispensaries, manufacturers, and cultivators.
Headquartered in Newtown, PA, Forian has carved a niche in the industry by providing unparalleled insights through their data products. By integrating and normalizing large-scale healthcare data, Forian creates distinctive information assets and proprietary insights, tailored to meet the diverse needs of their clients.
Forian’s recent achievements include a strategic stock repurchase, indicating their robust financial health and confidence in their growth trajectory. Additionally, the company has demonstrated consistent revenue growth and positive Adjusted EBITDA, reflecting its operational efficiency and market positioning.
Forian also emphasizes collaboration and partnerships to enhance its product offerings. Their data management and analytics solutions are designed to support the evolving needs of the healthcare and life sciences industries, driving better decision-making and outcomes.
Stay updated with Forian's latest news and developments as the company continues to innovate and lead in the realm of data-driven healthcare solutions.
Forian Inc. (Nasdaq: FORA) reported a 37% year-over-year revenue growth in Q4 2022, totaling $7.9 million, with healthcare information revenue increasing 64%. The company reduced its net loss to $3.6 million or $0.11 per share, down from $8.0 million in Q4 2021. For the full year, total revenue reached $28.0 million, a 66% increase from 2021. Forian divested BioTrack for $30 million in February 2023, enhancing its balance sheet. The company expects 25% to 37% revenue growth in healthcare information in 2023, aiming for positive adjusted EBITDA in the second half of the year.
Forian Inc. (Nasdaq: FORA) announced it will release its fourth quarter and full year 2022 financial results on March 27, 2023, after market close. A conference call and webcast will follow at 4:30 p.m. (ET) the same day. Investors can register for the call and access the webcast live on the company’s website. Forian provides data science-driven information and analytics solutions to healthcare and life sciences sectors, focusing on optimizing operational and financial performance for its clients. Forward-looking statements highlight potential risks and uncertainties that may affect future performance, suggesting caution in reliance on these projections.
FAQ
What is the current stock price of Forian (FORA)?
What is the market cap of Forian (FORA)?
What does Forian Inc. specialize in?
Who are Forian's primary customers?
What recent financial achievements has Forian accomplished?
How does Forian provide value to its clients?
Where is Forian Inc. headquartered?
What are some of Forian's latest updates?
How does Forian integrate data for its analytics solutions?
What makes Forian's data products unique?
How can investors stay informed about Forian's updates?
What sectors does Forian's expertise cover?
